Details for Patent: 11,382,917
✉ Email this page to a colleague
Which drugs does patent 11,382,917 protect, and when does it expire?
Patent 11,382,917 protects TADLIQ and is included in one NDA.
This patent has nine patent family members in nine countries.
Summary for Patent: 11,382,917
| Title: | Liquid oral formulations for tadalafil |
| Abstract: | The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc. |
| Inventor(s): | Pandya; Jinal (Unjha, IN), Mehta; Sandip P. (Ahmedabad, IN), Umrethia; Manish (Ahmedabad, IN), Mandal; Jayanta Kumar (Ahmedabad, IN), Pansuriya; Hiren (Ahmedabad, IN) |
| Assignee: | LIQMEDS WORLDWIDE LIMITED (Haynes, GB) |
| Application Number: | 17/403,282 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 11,382,917
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmp Dev Llc | TADLIQ | tadalafil | SUSPENSION;ORAL | 214522-001 | Jun 17, 2022 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | TADLIQ IS INDICATED FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) (WHO GROUP 1) TO IMPROVE EXERCISE ABILITY | ⤷ Try a Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 11,382,917
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| India | 201721046640 | Dec 26, 2017 |
| India | 201821012438 | Apr 2, 2018 |
International Family Members for US Patent 11,382,917
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2018397436 | ⤷ Try a Trial | |||
| Brazil | 112020012986 | ⤷ Try a Trial | |||
| Canada | 3086881 | ⤷ Try a Trial | |||
| China | 111683683 | ⤷ Try a Trial | |||
| European Patent Office | 3731870 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
